CIRM Funded Clinical Trials
Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A
Disease Area:
Neurological Disorders, Other
Trial Sponsor:
University of California, San Diego
Trial Stage:
Phase 1/2
Trial Status:
Launching
Targeted Enrollment:
N/A
